Litcius/Paper detail

First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation

Thierry Landre, Gaëtan Des Guetz, Kader Chouahnia, Boris Duchemann, Jean‐Baptiste Assié, C. Chouaïd

2020Journal of Cancer Research and Clinical Oncology22 citationsDOIOpen Access PDF

Topics & Concepts

ErlotinibMedicineInternal medicineBevacizumabErlotinib HydrochlorideRamucirumabEpidermal growth factor receptorLung cancerOncologyTyrosine-kinase inhibitorCancerChemotherapyLung Cancer Treatments and MutationsLung Cancer Research StudiesLung Cancer Diagnosis and Treatment
First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation | Litcius